Biocytogen

company

About

Biocytogen is a biopharmaceutical company that provides integrated solutions for antibody drug development.

  • 1001 - 5000

Details

Last Funding Type
Series D
Last Funding Money Raised
¥543M
Industries
Biotechnology,Health Care,Medical Device,Therapeutics
Founded date
Nov 1, 2008
Number Of Employee
1001 - 5000
Operating Status
Active

Biocytogen is a biopharmaceutical company that provides biomedical communities with integrated solutions for antibody drug development. Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMabTM Mouse), and in vivo/in vitro preclinical validation studies, using gene editing technologies and a state-of-the-art animal facility. Biocytogen works with the world's leading pharmaceutical and biotechnology companies.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
¥1.51B
Biocytogen has raised a total of ¥1.51B in funding over 2 rounds. Their latest funding was raised on Sep 15, 2020 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 15, 2020 Series D ¥0.97B 1 Detail
Aug 8, 2019 Series D ¥543M 1 China Life Healthcare Fund Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Biocytogen is funded by 1 investors. China Life Healthcare Fund are the most recent investors.
Investor Name Lead Investor Funding Round
China Life Healthcare Fund Series D